Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CELLAVISION AB

CellaVision AB provides digital solutions for medical microscopy in the field of hematology, with its product portfol... read more Featured Products: More products

Download Mobile App





Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022

CellaVision (Lund, Sweden) has announced the launch of DIFF-Line by CellaVision, a new workflow solution for low-volume hematology laboratories at the 2022 AACC Clinical Lab Expo. More...

DIFF-Line by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision DC-1, RAL SmearBox, and RAL StainBox.

CellaVision DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision DC-1 was launched in 2019 and received FDA clearance in October 2020.

RAL SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market today July 27, 2022.

RAL StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.

DIFF-Line by CellaVision is available on the European market from July 2022 and will be rolled out in more markets in 2022. All CellaVision products are sold through their distribution partners.

“DIFF-Line by CellaVision is a comprehensive solution for small labs that want to improve diagnostic certainty,” said Simon Ostergaard, CellaVision CEO. “With the acquisition of RAL Diagnostics, CellaVision can now offer a complete workflow for smearing, staining, and analyzing peripheral blood smears in hematology labs that handle a smaller amount of daily blood samples.”

Related Links:
CellaVision 


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.